Welcome to our dedicated page for Annexon SEC filings (Ticker: ANNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Annexon SEC filings document a clinical-stage biopharmaceutical company developing C1q-targeted immunotherapies for neuroinflammatory and classical complement-mediated diseases. Its Form 8-K reports furnish operating results, portfolio progress, investor presentations, and strategic priority updates tied to programs such as vonaprument, tanruprubart, and ANX1502.
The company’s filings also cover proxy governance, annual meeting proposals, director elections, auditor ratification, executive compensation votes, board changes, and Nasdaq-listed common stock. Capital-structure disclosures include amendments to common stock purchase warrants and related rights of security holders.